Previous close | 0.2500 |
Open | 0.2500 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 7.50 |
Expiry date | 2024-07-19 |
Day's range | 0.2500 - 0.2500 |
Contract range | N/A |
Volume | |
Open interest | 21 |
CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical products announced today the following: On April 12, 2024 CASI submitted the IND application to the FDA for CID-103 to support a phase 1/2 study of CID-103 in adults with chronic Immune Thrombocytopenia (ITP). On May 13, 2024 CASI received a letter from FDA indicating that study may proceed.
CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported financial results for the three months ended March 31, 2024.
With the business potentially at an important milestone, we thought we'd take a closer look at CASI Pharmaceuticals...